13th Process Development for Highly Potent Drugs Summit (HPAPI)

Temi della conferenza
From Process Safety to Rapid Scale-Up to Tech Transfer: Integrating Process Development, Industrial Hygiene and Equipment Selection to Achieve GMP Manufacturing of Novel High Potent Drug Compounds 2023 has been a pivotal year for novel high potent compounds securing early success and approvals – from Henlius’s ADC to Gilead’s Trodelvy to BMS’s Augtyro, cementing the growth of highly potent drugs market to reach USD$40.7bn by 2023.

Professional congress organizer (PCO)
Hanson Wade Group

Annotazioni
URL:
Brochure: https://go.evvnt.com/2316046-3?pid=4832

Speakers: Antonio Hernandez-Cardoso, Senior Principal Scientist, US Pharmacopiea, and more

https://go.evvnt.com/2316046-2?pid=4832

Ms. Gracia Carr